FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...

Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for ...

FibroGen (FGEN) announced that the China State Administration for Market Regulation approved the sale of FibroGen International to AstraZeneca ...

Analysts anticipate FibroGen to report an earnings per share (EPS) of $-0.30. Investors in FibroGen are eagerly awaiting the ...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now ...

FibroGen emphasized that the increased expected proceeds from the China sale and the extended cash runway support advancement of its lead programs, with FG-3246 and FG-3180 Phase II trials set to ...

View FibroGen, Inc. FGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.

(FGEN) on Monday reported a loss of $7.6 million in its second quarter. On a per-share basis, the San Francisco-based company said it had a ...

May 5 (Reuters) - FibroGen Inc (FGEN.O), opens new tab said on Friday its anemia drug had failed to meet the main goal in a late-stage trial, sending its shares tumbling nearly 12% before the bell ...

Conference Call and Webcast Presentation The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A ...

FibroGen has been excited about the drug, as CEO Tom Neff told me last month, because it could reverse fibrosis that leads to scarring of the liver, lungs and arteries.

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen (FGEN), Inc. today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong ...